A retrospective study of DA-EPOCH with or without rituximab therapy for aggressive lymphoma
Not Applicable
- Conditions
- Malignant Lymphoma
- Registration Number
- JPRN-UMIN000025698
- Lead Sponsor
- Shimane University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
Primary CNS lymphoma
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 4-year overall survival
- Secondary Outcome Measures
Name Time Method Safety (Incidence of hematological toxicities, non-hematological toxicities including febrile neutropenia and etc.)